Live Catalyst Benchmark
Endpoint Index
A live benchmark for clinical-trial readout risk. Every active Endpoint Arena market gets the same weight, then the basket marks to current YES odds so you can track, compare, and hedge catalyst exposure.
ECI live tape
One number for the market's current view of active trial readouts.
Index Level
42.7%
Active Markets
3
Index Level
42.7%
Equal-weight YES price across active trial markets.
Move From Open
+0.4 pts
Started at 42.3% across the same equal-weight basket.
Live Constituents
3
2 resolved markets excluded from the live benchmark.
Basket Volume
$10
35 trades across constituents.
Index History
Equal-weight benchmark level over time
Latest
83.9%
Since Start
+41.5 pts
Markets
3
Index Level
42.7%
Indicative Range
31%-55%
0%50%100%
Research benchmark only. This is not an ETF, security, or offer to trade.
Sleeves
Immunology1 market
YES79.7%
Move+6.6 pts
Oncology1 market
YES0.0%
Move-22.0 pts
Other1 market
YES48.4%
Move+16.4 pts
Upcoming Readouts
Constituents
3 active markets at equal weight
Trial
Sleeve
YES
Move
Weight
Volume
Sonelokimab in Psoriatic Arthritis
MLTXPhase 3NCT06641076
Week 16 ACR50 response versus placebo
Immunology
YES
79.7%
Move
+6.6
Weight
33.3%
Volume
$0
79.7%
+6.6
33.3%
$0
GPS Maintenance Therapy in AML Remission
SLSPhase 3NCT04229979
Overall survival for GPS versus best available therapy
Oncology
YES
0.0%
Move
-22.0
Weight
33.3%
Volume
$3
0.0%
-22.0
33.3%
$3
ABS-201 in Androgenetic Alopecia
ABSIPhase 1/Phase 2NCT07317544
Target Area Hair Count (TAHC)
Other
YES
48.4%
Move
+16.4
Weight
33.3%
Volume
$6
48.4%
+16.4
33.3%
$6